COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Protocol No
TAKEDA-TAK-981-1503
Principal Investigator
Meera Mohan
Phase
I/II
Summary
This study is being done to determine the safety and tolerability of TAK-981 in combination with monoclonal antibodies in patients with R/R MM and to determine the recommended Phase 2 dose. Phase 2 is being done to evaluate the efficacy of TAK-981 in combination with monoclonal antibodies in patients with RRMM
Description
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL